Attached files
| file | filename |
|---|---|
| 10-K - 10-K - TELA Bio, Inc. | tela-20201231x10k.htm |
| EX-32.2 - EX-32.2 - TELA Bio, Inc. | tela-20201231ex322c48d9b.htm |
| EX-32.1 - EX-32.1 - TELA Bio, Inc. | tela-20201231ex3215876b9.htm |
| EX-31.2 - EX-31.2 - TELA Bio, Inc. | tela-20201231ex3124d7ac8.htm |
| EX-31.1 - EX-31.1 - TELA Bio, Inc. | tela-20201231ex311184b56.htm |
| EX-21.1 - EX-21.1 - TELA Bio, Inc. | tela-20201231ex211c6241e.htm |
| EX-10.29 - EX-10.29 - TELA Bio, Inc. | tela-20201231ex1029d9875.htm |
| EX-10.12 - EX-10.12 - TELA Bio, Inc. | tela-20201231ex1012fa3ea.htm |
| EX-10.11 - EX-10.11 - TELA Bio, Inc. | tela-20201231ex1011ec62a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
TELA Bio, Inc.:
We consent to the incorporation by reference in the registration statements on Form S-3 (No. 333-251505) and Form S-8 (Nos. 333-245707 and 333-235241) of TELA Bio, Inc. of our report dated March 25, 2021, with respect to the consolidated balance sheets of TELA Bio, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes, which report appears in the December 31, 2020 annual report on Form 10-K of TELA Bio, Inc.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 25, 2021